Biotechnology · NASDAQ
Current Price
$143.82
PE Ratio (TTM)
7.1x
Intrinsic Value
Outside reliable range
COMPETITIVE MOAT
↑Proprietary RNAi Technology Platform
Alnylam possesses a leading, proprietary RNA interference (RNAi) platform. This deep scientific expertise and intellectual property create a significant barrier to entry for competitors seeking to replicate their therapeutic approach.
↑First-Mover Advantage in RNAi Therapeutics
As a pioneer in RNAi, Alnylam has established a strong first-mover advantage. This allows them to build market share and brand recognition before significant competition emerges in specific therapeutic areas.
↑Strong Clinical Pipeline and Data
The company's robust pipeline, supported by compelling long-term data like the HELIOS-B results, demonstrates its ability to develop and validate novel therapies. This track record builds investor and physician confidence.
INVESTMENT RISKS
↓Commercialization Execution Risk
Concerns about slower patient starts and demand for Amvuttra highlight the risk of execution challenges in commercializing new therapies. Meeting market expectations is crucial for sustained growth.
↓Pipeline Development and Clinical Trial Failures
Despite a strong pipeline, the inherent risk of clinical trial failures or unexpected safety issues remains. A significant setback in a key program could severely impact future revenue.
↓Investor Sentiment and Stock Volatility
Recent significant stock price drops and investigations indicate high investor sensitivity to demand concerns and potential fraud allegations. This volatility can impact capital access and valuation.
Base case
Base case assumptions: 15.2% annual earnings growth, 7.06x target PE, 10% discount rate, 5 year projection. Data as of 2026-11-20.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Alnylam Pharmaceuticals, Inc. respond.
Open PE Calculator for ALNYAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
PE Ratio (TTM)
7.1x
PEG Ratio
0.00
Earnings Yield
14.15%
ROE (TTM)
159.7%
Revenue/Share (TTM)
$37.46
Debt/Equity
0.35x
The trailing twelve-month PE ratio of ALNY reflects how much investors pay per dollar of Alnylam Pharmaceuticals, Inc.'s earnings. This metric is most useful when compared to Biotechnology peers and the company's own historical range.
ALNY's PE of 7.1x combined with a PEG ratio of 0.00 provides a growth-adjusted perspective. A PEG below 1.0 means the P/E is low relative to the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Biotechnology, a DCF analysis may be more appropriate.
To value Alnylam Pharmaceuticals, Inc. using PE: (1) Compare the current PE (7.1x) against the Biotechnology median to assess relative pricing, (2) check the PEG ratio (0.00) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
ALNY's PEG ratio is 0.00, calculated by dividing the PE ratio (7.1x) by the expected earnings growth rate. A PEG below 1.0 means the P/E is low relative to the expected earnings growth rate. Note that PEG accuracy depends on the reliability of growth estimates.
PE ratio gives a quick relative read — how ALNY is priced versus Biotechnology peers. DCF provides an absolute value based on projected free cash flows. For ALNY, with a strong ROE of 159.7%, both methods are worth using — PE for a market-relative check, DCF to stress-test whether fundamentals justify the price. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
P/E and DCF value ALNY with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.